ARCHIVES

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

This article is from The Cancer Letter archive.

Vol. 13 No. 19 | May 8, 1987

Download PDF Visit The Full Archive

Related Articles

Number of Clinical R01 Applications Doubles; Funding Rate Below 20%; NCI Execs Not Satisfied

July 17, 1992

Panel Objects To Act Change Requiring NCI Carcinogen Report

May 12, 1978

DCPTC Proceeding With Plans For Intramural Lab

January 30, 1987

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

Center For Health Policy And Outcomes Established At Memorial Sloan Kettering. ONS Marks 35th Year.

July 9, 2010

12 Minority CCOPs Awardees Names, San Antonio Gets 2

September 21, 1990